CULPRIT-SHOCK
Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock
| Coordinatore | UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Sito del progetto | http://www.culprit-shock.eu |
| Totale costo | 7˙803˙369 € |
| EC contributo | 5˙999˙145 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2017-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAET ZU LUEBECK
Organization address
address: RATZEBURGER ALLEE 160 contact info |
DE (LUEBECK) | coordinator | 1˙818˙072.00 |
| 2 |
STIFTUNG INSTITUT FUR HERZINFARKTFORSCHUNG LUDWIGSHAFEN
Organization address
address: BREMSERSTRASSE 79 contact info |
DE (LUDWIGSHAFEN) | participant | 837˙720.00 |
| 3 |
A.C.T.I.O.N ALLIES IN CARDIOVASCULAR TRIALS INITIATIVES AND ORGANIZEDNETWORKS ASSOCIATION
Organization address
address: BOULEVARD DE L HOPITAL 47 contact info |
FR (PARIS) | participant | 599˙580.00 |
| 4 |
UNIVERSITAET LEIPZIG
Organization address
address: RITTERSTRASSE 26 contact info |
DE (LEIPZIG) | participant | 512˙439.00 |
| 5 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 394˙420.00 |
| 6 |
Academisch Medisch Centrum bij de Universiteit van Amsterdam
Organization address
address: MEIBERGDREEF 9 contact info |
NL (AMSTERDAM) | participant | 384˙720.00 |
| 7 |
UNIVERSITY OF GLASGOW
Organization address
address: University Avenue contact info |
UK (GLASGOW) | participant | 227˙045.00 |
| 8 |
HERZZENTRUM LEIPZIG GMBH
Organization address
address: STRUEMPELLSTRASSE 39 contact info |
DE (LEIPZIG) | participant | 212˙100.00 |
| 9 |
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Organization address
address: 3 Avenue Victoria contact info |
FR (PARIS) | participant | 195˙900.00 |
| 10 |
NATIONAL WAITING TIMES CENTRE BOARD
Organization address
address: BEARDMORE STREET CLYDEBANK contact info |
UK (GLASGOW) | participant | 189˙719.00 |
| 11 |
INSTYTUT KARDIOLOGII IM. PRYMASA TYSIACLECIA STEFANA KARDYNALA WYSZYNSKIEGO
Organization address
address: ul. Alpejska 42 contact info |
PL (WARSZAWA) | participant | 138˙600.00 |
| 12 |
INSELSPITAL-STIFTUNG
Organization address
address: FREIBURGSTRASSE 18 contact info |
CH (BERN) | participant | 105˙750.00 |
| 13 |
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Organization address
address: WILRIJKSTRAAT 10 contact info |
BE (EDEGEM) | participant | 85˙000.00 |
| 14 |
ARCISPEDALE SANTA MARIA NUOVA AZIENDA OSPEDALIERA
Organization address
address: VIALE UMBERTO I 50 contact info |
IT (REGGIO EMILIA) | participant | 80˙280.00 |
| 15 |
VIESOJI ISTAIGA VILNIAUS UNIVERSITETO LIGONINES SANTARISKIU KLINIKOS
Organization address
address: SANTARISKIU G 2 contact info |
LT (VILNIUS) | participant | 75˙720.00 |
| 16 |
UNIVERZITETNI KLINICNI CENTER LJUBLJANA
Organization address
address: ZALOSKA CESTA 002 contact info |
SI (LJUBLJANA) | participant | 72˙000.00 |
| 17 |
VEREIN ZUR FOERDERUNG DER WISSENSCHAFTLICHEN FORSCHUNG AM WILHELMINENSPITAL DER STADT WIEN
Organization address
address: Montleartstrasse 37 contact info |
AT (WIEN) | participant | 45˙960.00 |
| 18 |
AZIENDA OSPEDALIERA DELLA PROVINCIA DI LECCO
Organization address
address: VIA DELL'EREMO 9/11 contact info |
IT (LECCO) | participant | 24˙120.00 |
| 19 |
UPPSALA UNIVERSITET
Organization address
address: SANKT OLOFSGATAN 10 B contact info |
SE (UPPSALA) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the initiation of cardiogenic shock, or 2) treat additional lesions considered hemodynamically significant but not acutely triggering the CS cascade as well. Current guidelines recommend percutaneous coronary intervention of all critical lesions. However, due to a lack of randomized trials, these recommendations are solely based on registry data and pathophysiological considerations. Aim of the randomized CULPRIT-SHOCK trial is therefore to compare a) immediate multivessel PCI versus b) culprit lesion only PCI in patients with AMI complicated by CS. A total of 706 CS patients will be randomized in several European countries. The primary endpoint will be 30-day all-cause mortality and/or severe renal failure requiring renal replacement therapy. CULPRIT-SHOCK will therefore determine the optimal percutaneous revascularization strategy in patients with AMI and multivessel disease complicated by CS. In addition, a comprehensive array of efficacy, safety and socio-economic parameters for the chosen population will be assessed. Multiple secondary endpoints and several substudies (microcirculation, biomarkers, angiography) will serve to further understand the presumed differential effects of the 2 treatment arms and to understand the underlying pathophysiology and prognostic markers. From these parameters a multivariable regression model and a risk score for the prediction of clinical prognosis and a cost-effectiveness model in AMI and CS will be developed. Furthermore, CULPRIT-SHOCK will obtain data on CS patients not meeting inclusion criteria by instituting a separate registry.'